Company Description

20/20 OptimEyes' MNP (Mucoadhesive Nanoparticles) platform delivers small-molecule drugs directly to mucosal surfaces via a mucoadhesive polymer system that enables sustained, localized drug release. This approach improves bioavailability, compliance and safety, and supports topical delivery for multiple indications. The technology is applicable to all mucosal surfaces, across ophthalmology, respiratory, urogenital, women’s health, oncology and CNS pathologies.